- Stocks
- Pharma & Healthcare
- Alembic
Alembic share price
NSE: ALEMBICLTDPharma & HealthcareReal Estate - Development
Alembic at a glance
Alembic (NSE: ALEMBICLTD) closed at ₹95.20 on 19 Oct 2026, down 2.46% on the day. With a market capitalisation of ₹2,445 Cr, it ranks 1068th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Real Estate - Development.
At its last close the stock traded at 7.7× trailing earnings, against a return on equity of 13.0% in FY26. Over the past year the share price has fallen 2.8%. Its 52-week range is ₹68.62 (30 Mar 2026) to ₹117.72 (3 Sep 2026); the last close is 19.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹150 Cr (+10.6% year on year) and net profit ₹16 Cr (+6.7%), on a standalone basis. Promoters held 70.88% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,445 CrRank 1068 on NSE
- P/E (trailing)
- 7.7×
- Price to book
- 0.74×FY26
- EPS (TTM)
- ₹20.03to Q4 FY26
- ROE
- 13.0%FY26
- ROCE
- 6.1%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 52.5%FY26
- Book value / share
- ₹95.22FY26
- Dividend payout
- 19.4%FY26
- 52-week high
- ₹117.723 Sep 2026
- 52-week low
- ₹68.6230 Mar 2026
- 1-year return
- −2.8%
- RSI (14-day)
- 38.8
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.46% | −5.7% | −6.9% | +8.0% | −2.8% |
Alembic quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹84 Cr | ₹110 Cr | ₹123 Cr | ₹135 Cr | ₹94 Cr | ₹118 Cr | ₹141 Cr | ₹150 Cr |
| Revenue YoY | +7.6% | +10.7% | +4.9% | +6.6% | +12.3% | +7.1% | +14.9% | +10.6% |
| Net profit | ₹5 Cr | ₹12 Cr | ₹19 Cr | ₹15 Cr | ₹8 Cr | ₹14 Cr | ₹19 Cr | ₹16 Cr |
| Net profit YoY | −34.1% | +72.3% | +10.3% | +11.1% | +79.9% | +18.3% | +1.0% | +6.7% |
| Net margin | 5.5% | 10.7% | 15.7% | 11.2% | 8.8% | 11.9% | 13.8% | 10.8% |
| EPS | ₹1.60 | ₹4.08 | ₹6.66 | ₹5.25 | ₹2.87 | ₹4.83 | ₹6.73 | ₹5.60 |
Alembic financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹74 Cr | ₹78 Cr | ₹127 Cr | ₹157 Cr | ₹222 Cr | — |
| Operating profit | ₹17 Cr | ₹98 Cr | ₹97 Cr | ₹103 Cr | ₹156 Cr | — |
| Net profit | ₹14 Cr | ₹86 Cr | ₹81 Cr | ₹93 Cr | ₹145 Cr | — |
| EPS (₹) | ₹13.00 | ₹9.00 | ₹7.00 | ₹10.00 | ₹12.00 | — |
| Cash from operations | −₹2 Cr | −₹18 Cr | ₹39 Cr | ₹23 Cr | ₹86 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹7 Cr | ₹11 Cr | ₹7 Cr |
| Shareholders' equity | ₹2,297 Cr | ₹2,497 Cr | ₹2,078 Cr | ₹2,186 Cr | ₹2,339 Cr | ₹2,445 Cr |
Alembic shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.88% | 70.88% | 70.88% | 70.88% | 70.88% | 70.88% |
| Foreign institutions | 1.66% | 1.50% | 1.38% | 1.28% | 1.25% | 1.25% |
| Domestic institutions | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Non-institutions | 27.41% | 27.57% | 27.69% | 27.78% | 27.82% | 27.81% |
Alembic vs peers
The listed Pharma & Healthcare companies nearest to Alembic by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
| HIKALHikal | ₹217.00 | +0.46% | −12.6% | ₹2,676 Cr | — | — |
| DRAGARWQDr Agarwals Eye Hospital | ₹5,083.50 | +0.46% | — | ₹2,457 Cr | — | — |
| ALEMBICLTDAlembic | ₹95.20 | −2.46% | −2.8% | ₹2,445 Cr | 7.7 | — |
| VENUSREMVenus Remedies | ₹1,796.10 | +5.00% | +293.9% | ₹2,401 Cr | 23.3 | — |
| FREDUNFredun Pharmace | ₹1,435.00 | −3.04% | — | ₹2,373 Cr | 23.4 | — |
| DCALDishman Carbogen Amcis | ₹146.03 | −2.65% | −50.3% | ₹2,290 Cr | 23.5 | — |
Ask anything about Alembic
Pivot answers on the live chart with evidence you can check, and tests strategies against ALEMBICLTD's own history. Try: “Why has ALEMBICLTD moved over the last three months?” · “Backtest a 50-day moving-average crossover on ALEMBICLTD over five years” · “Compare ALEMBICLTD with DPC02 on margins and valuation”
Frequently asked questions about Alembic
What is the share price of Alembic today?
Alembic (NSE: ALEMBICLTD) last closed at ₹95.20 on 19 Oct 2026. Its 52-week high is ₹117.72 and its 52-week low is ₹68.62.
What is the market cap of Alembic?
Alembic's market capitalisation is ₹2,445 Cr (₹2,445 Cr) at the 19 Oct 2026 close, ranking 1068th among the NSE companies Pivot tracks.
What is the P/E ratio of Alembic?
Alembic trades at a trailing P/E of 7.7. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 23.4.
What is the ROE and ROCE of Alembic?
Return on equity was 13.0% in FY26 and return on capital employed was 6.1% in FY26 (consolidated figures).
Is Alembic a debt-free company?
Alembic is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Alembic's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Alembic reported revenue of ₹150 Cr, +10.6% year on year, and net profit of ₹16 Cr, +6.7% year on year.
How has Alembic stock performed over the last year?
Alembic's share price has fallen 2.8% over the past year, +8.0% over three months and −6.9% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Alembic?
As of 30 Jun 2026: promoters 70.88%, foreign institutions 1.25%, domestic institutions 0.05%, non-institutions 27.81%.
Who are Alembic's competitors?
The listed Pharma & Healthcare companies closest to Alembic by market cap are Dishman Pharma, Hikal, Dr Agarwals Eye Hospital, Venus Remedies, Fredun Pharmace and Dishman Carbogen Amcis.
Is Alembic a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Alembic's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALEMBICLTD against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text